| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5474756 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US6143274 | BRACCO | Method for imaging and radiopharmaceutical therapy using 1-substituted-4,7,10-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2012
(11 years ago) | |
| US5846519 | BRACCO | Method for imaging mammalian tissue using 1-substituted-1,4,7-tricarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs |
Dec, 2015
(8 years ago) | |
Prohance Multipack is owned by Bracco.
Prohance Multipack contains Gadoteridol.
Prohance Multipack has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Prohance Multipack are:
- US5474756
- US6143274
- US5846519
Prohance Multipack was authorised for market use on 09 October, 2003.
Prohance Multipack is available in injectable;injection dosage forms.
Prohance Multipack can be used as contrast agent for magnetic resonance imaging.
The generics of Prohance Multipack are possible to be released after 08 December, 2015.
Drugs and Companies using GADOTERIDOL ingredient
Market Authorisation Date: 09 October, 2003
Treatment: Contrast agent for magnetic resonance imaging
Dosage: INJECTABLE;INJECTION
PROHANCE MULTIPACK family patents
